John V. Oyler
Co-Founder, Chairman, and CEO, BeiGene
At BeiGene, John created a model in which internal teams run clinical trials, leveraging custom-built technologies to improve efficiency and the quality of execution. The company claims to have one of the industry’s largest oncology teams, alongside an $800 million biologics manufacturing and clinical R&D facility near Princeton, New Jersey, and an expanded therapeutic pipeline that includes more than 40 clinical or commercial programs and over 60 preclinical programs.
Under John’s leadership, more than 1.6 million patients have been treated with BeiGene’s medicines, to date. Now in its fifteenth year, BeiGene will rename to BeOne Medicines and redomicile to Switzerland in 2025, underscoring the company’s rapid global growth with more than 11,000 colleagues operating in 45 countries and regions.
“When I co-founded BeiGene in 2010, I realized that the rising costs of developing cutting-edge oncology medicines, coupled with persistent barriers to access, were creating a vicious cycle of inequality – where the ‘haves’ had access, and the ‘have-nots’ were left behind in terms of both access to care and affordability.”
